[{"id":"0db166ab-652a-4aef-9bdc-7b8481acede3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03562832","created_at":"2021-01-18T17:32:03.383Z","updated_at":"2024-07-02T16:34:26.059Z","phase":"Phase 2","brief_title":"Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP","source_id_and_acronym":"NCT03562832","lead_sponsor":"Allarity Therapeutics","biomarkers":" HER-2 • BRCA1","pipe":"","alterations":" ","tags":["HER-2 • BRCA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e stenoparib (2X-121)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/20/2018","start_date":" 06/20/2018","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2024-06-14"},{"id":"5e1c9af1-0597-4355-a89b-c38ee6769148","acronym":"","url":"https://clinicaltrials.gov/study/NCT01618136","created_at":"2021-01-18T06:56:05.409Z","updated_at":"2024-07-02T16:35:45.309Z","phase":"Phase 1/2","brief_title":"An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT01618136","lead_sponsor":"Eisai Limited","biomarkers":" HER-2 • ER • PGR • ATM","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR • ATM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • temozolomide • stenoparib (2X-121)"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 01/01/2012","start_date":" 01/01/2012","primary_txt":" Primary completion: 07/01/2015","primary_completion_date":" 07/01/2015","study_txt":" Completion: 07/01/2015","study_completion_date":" 07/01/2015","last_update_posted":"2023-06-19"},{"id":"7eb4804e-e312-4742-a59c-d9255aa4ec24","acronym":"","url":"https://clinicaltrials.gov/study/NCT05475184","created_at":"2022-07-26T17:10:16.436Z","updated_at":"2024-07-02T16:36:06.660Z","phase":"Phase 2","brief_title":"A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor","source_id_and_acronym":"NCT05475184","lead_sponsor":"Onconic Therapeutics Inc.","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nesuparib (JPI-547)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 08/01/2022","start_date":" 08/01/2022","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2022-07-26"}]